Company news

Veracyte, Inc. (NASDAQ:VCYT) news

Veracyte, Inc. news releases on 6ix. Latest, Sep 29, 2026: Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone…

Veracyte, Inc. (NASDAQ:VCYT) news

Press releases & updates

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Veracyte Announces Second Quarter 2026 Financial Results

Veracyte : to Release Second Quarter 2026 Financial Results on July 30, 2026

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

Vaxcyte to Participate in Upcoming Investor Conferences

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings

Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer

Veracyte Announces First Quarter 2026 Financial Results

Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers

Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte to Participate in Upcoming Investor Conferences

Veracyte Announces Third Quarter 2025 Financial Results

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care

Veracyte Announces Second Quarter 2025 Financial Results

Veracyte Set to Join S&P SmallCap 600

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

Veracyte Announces First Quarter 2025 Financial Results

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer